Insmed Incorporated stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Insmed Incorporated stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Insmed Incorporated do? Business model and key facts
Get the full picture of Insmed Incorporated: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 1664
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Stocks related to Insmed Incorporated
Selected based on industry alignment and relative market positioning.
Events and news impacting Insmed Incorporated stock
Earnings, coporate decisions and industry developments that can affect the share price.
Insmed Incorporated fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
